Chanticleer — Merger or Acquisition (October 2019)
22 slides from Chanticleer's merger presentation, Oct 16, 2019
Slide 1: Sonnet BioTherapeutics Corporate Presentation
&S S O N N FT Corporate Presentation BioTherapeutics October 2019
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements about Sonnet BioTherapeutics based on management's current expectations which are subject to known and unknown uncertainties and risks. Words such as “anticipated,” “initiate,” “expect,” “intend,” “plan,” “believe,” “se
Slide 3: Corporate Background
8 Corporate Background Incorporated in New Jersey = Headquarters: Princeton, New Jersey = Other Locations: New York City, Geneva Employees, Consultants and Contracted Scientists/Experts: Approximately 30 people Internal Pipeline Focus: Oncology = Proprietary technology platform = Existing licensing/
Slide 4: Corporate Highlights
Corporate Highlights Sonnet is a clinical stage biopharmaceutical company with a proprietary, modular biologic drug development platform We have a deep knowledge of cytokine biology, complemented by extensive drug discovery and development expertise Our corporate strategy comprises an internal thera
Slide 5: Strategic Investment Partner Secured
Strategic Investment Partner Secured Global Emerging Markets (GEM) is a multibillion dollar investment group with an established interest in Sonnet's success * In August 2019, through a share exchange agreement with Relief Therapeutics Holding SA (SIX: RLF), Sonnet acquired the rights to develop low
Slide 6: fe a
- O fe a 5 ai a 0) = Cc (@) Yn 10) po re 2 2 ° 2 0) fo) ” 2 = a fe) o fe) oO Cc pe) ES le) iS 0) = (0) fo) Ps © 2 3 < ” o B 5 0) D 3] 2 Ke) Q D 2 2 ‘6 Fe 2. 5 rs ‘fers
Slide 7: Pipeline Overview
Pipeline Overview First wave pipeline will target IL-6, IL-12, IL-15, IL-18, GMcSF and TGFp Program | Chemotherapy Induced Peripheral Neuropathy” S0N-1010 112A) —— ll or tox Pilot Efficacy SON-080 {low dose IL-6) Study Initiation SON-1210 (IL15-F,AB-ILI2} Undisclosed Solid Tumor Non-GLP Tox Preclini
Slide 8: IL-6: A Disease Modifier of CIPN
IL-6: A Disease Modifier of CIPN CIPN is a degeneration of nerve fibers resulting from chemotherapy In peripheral neurons, IL-6 triggers a series of pathways for the maintenance of mitochondrial function and axonal regeneration. MEK JAK PI3K Neuroprotection Axonal Regeneration Remyelination Mitochon
Slide 9: SON-080: Clinical History
SON-080: Clinical History Low dose recombinant human IL-6 is safe in cancer patients In Phase | studies comprising 214 total cancer patients: + SC delivery of IL-6 doses dependently increases plasmatic IL-6, with plasmatic 11/2 ~ 4 hours + In none of the trials was exacerbation of tumour burden obse
Slide 10: The Sonnet Technology Advantage
The Sonnet Technology Advantage Sonnet’s Fully Human Albumin Binding (F,AB) technology utilizes a single chain antibody fragment (scFv) capable of delivering one or two active biologic compounds + Therapeutic payloads attached via flexible linker peptides Following administration, Sonnet's F,,AB-der
Slide 11: pK t1/2 of FcAB Constructs IL-12 and IL-15
pK t1/2 of FyAB Constructs IL-12 and IL-15 The aim of this study was to demonstrate in mice, the pharmacokinetic (pK) behavior of naked IL-12 and IL-15 compared to the same fusion proteins linked to Sonnet’s FyAB domain Method: 8 mice C57B/TP, Age 9.5 weeks dose IV, sacrificed @ 5, 15, 30 mins, I, 2
Slide 12: Evaluating anti-TGFb and anti-TGFb-FcAB Tumor Accumulation
Evaluating anti-TGFg and anti-TGFg-F,AB Tumor Accumulation An in vivo Demonstration of F,,AB Proof-of-Concept Resulfs show an accumulation and Western blot analysis of Mouse 4T1 (TGFB-positive) tumor (~150mm?) extracts from mice terminated retention of F,AB in the tumor at 0.5, 4, 12 and 24-hours po
Slide 13: IL12-FcAB vs IL-12
IL12-F,AB vs IL-12 Comparison of Tumor Volumes Between Groups on Day 10 Post Treatment (Day 0 @ 100 mm) — 1L12 vs IL12-F,AB Single Dose E MM Gi: Vehicle = 25 E - G2: I-12 Boo s Mc: ans ce ? E « MM G4: IL-2 10ug : 15 z MM G5: IL12-F,AB « MM cé IL-2 oi 4 6 8 10 Treatment Groups MM G7: IL12-FYAB 7 Bays
Slide 14: IL12-FcAB vs IL-12
IL12-F,AB vs IL-12 Evaluation of Single Dose (SD) IL12-F,AB (1.3yg) vs IL-12 (30yg) in B16F10 Melanoma (established @100 mm3 , n=8) Tumor m@& Placebo 2857 2a eme LIZA 1D) = Molar} 074g] of IL-12 = 2000 J ee IL-12 (30ug, SD) 1996 Esco 3 1:30 ratio of IL-12 i bean { 1002 = SRRNNEL Volume PBS IL12 IL12
Slide 15: IL15-FAB-IL12
8 IL15-FAB-IL12 Efficacy in Melanoma Mouse Model Enhanced Reciprocal Biologic Activity: I-12: f IL-15 alpha receptor, IFN, NK/T cells, TH] and | TReg 1s FAB IL-15: fIL-12 beta 1 receptor, tNK cells, CD8 memory and |apoptosis IL-12 activates T cells and increases CD8 number, hence Sonnet’s 1L15-F,,AB
Slide 16: IL15-FAB-IL12 vs IL12-FcAB
IL15-FAB-IL12 vs IL12-F,AB Single I.V. Dose @ 100 mm? SC B16F10 Day 10 Tumor Volume (n=8) 1500 Sonnet Bi-Specific Construct _ IL15-F,4AB-IL12 t E i000 Synergistic Biologic Activity: : 3 IL-12: 1L-15 alpha receptor, IFN, 5 500 NK/T cells, TH] and | Treg 5 IL-15: f IL-12 beta 1 receptor, NK 2 ° cells
Slide 17: IL15-FcAB-IL12 vs Concomitant IL-12 and IL-15
IL15-F,AB-IL12 vs Concomitant IL-12 and IL-15 . Day 11 i= 2000-4 Day 11 vehicle at +3000m% not shown oO MB IL-12 (5g) + IL-15 (1g) § MB IL12-F,AB-L15 (1.5yg) s MM IL12-F,,AB-IL15 (6ug) 6 IL15-FyABALI2 (1.5} £ 10004 ll 1L15-FyAB-L12 (1.5ug) 5 Ml IL15-F,,AB-IL12 (ug) E ot 1L15-F,,AB-IL12 shows better
Slide 18: Business Strategy
Business Strategy A Three-Pronged Approach SEQNNEL
Slide 19: Execution Efficiency
8 Execution Efficiency Integrating a Best-in-Class Platform with a World-Class Development Strategy Cell Line - 112-F,AB Sartorius 115-F,AB-IL12 CRO Exploring innovative ae Leadership: Analytics - clinical plans cone SONNET Bio-outsource a Latham BioPharm 1L12-FyAB IL-6 1L15-FyAB-IL12 Identified CRO
Slide 20: Comparable Companies
Comparable Companies Select Oncology IPOs, ‘18/19 Ticker z Tead Ansel Pre-Money MK CurentSlage of Mos! Current MT |Comecny Nes Symbol 0 Dale Ineronewic Maca Siage atlPO Cap (SM) ‘Advanced Asset Cap (3M)** ‘prea Therapeutios APRE 10/3/2019 Targeted small molecules PI/2 213 PI/2 401 1GM Biosciences IG
Slide 21: Leadership
Leadership Accomplished management team with deep experience in biotechnology Pankaj Mohan, PhD Founder, CEO & Chairman Biotechnology entrepreneur with start- up. acaderric. large biopharma and goverment experience, Founded Oncobiologics in 2011 and. Jedi to a successful IPO in 2016 (Nasdaq: ONS). M
Slide 22: Company Highlights
Company Highlights Sonnet is a compelling opportunity A Dynamic Platform For Biopharmaceutical Development * Sonnet controls an enabling technology for innovating therapeutic products across multiple disease areas * As amodular, plug-and-play construct capable of being linked to multiple different c
Chanticleer Holdings — Merger or Acquisition (October 2019) on 6ix